Giant Biogene Holding Co., Ltd is a biotechnology company focused on recombinant collagen research, development, and commercialization. The company operates in the medical device and professional skincare sectors, offering products such as Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers and Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution. Its brand portfolio includes KOMFYMED, which focuses on professional skincare, Collgene, which emphasizes self-acceptance and recombinant technology, and Ke Yu, which integrates health protection into daily life. Giant Biogene serves both medical professionals and mass consumers through an omni-channel network that includes direct sales, offline brand experience stores, and retail partners such as Sephora and China Duty Free Group. The company markets its products in China and internationally across North America, Southeast Asia, and East Asia. It maintains a significant research pipeline with over 140 projects and holds numerous patents, participating in the drafting of industry standards for recombinant collagen dressings.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage xajuzi.com
Sector Healthcare IR page ir.xajuzi.com
Tags
recombinant collagen, medical devices, professional skincare, cosmetics, biomanufacturing, dermatology, consumer health, KOMFYMED, Collgene, Ke Yu, Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers, Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution
Press page —

Metrics

Valuation  
Market cap HK$ 20.01B
Market cap (USD) $ 2.55B
P/E 9.14
PEG 0.38
P/BV 1.81
P/S 3.19
P/OCF 9.17
P/FCF —
Dividend yield 7.4%
Turnover / mcap 0.34%
Returns  
ROE 22.5%
ROI 19.3%
ROIC 19.3%
Profit margin 34.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 24.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -6.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 5.519B 5.539B 3.524B 2.364B 1.552B
Net profit 1.915B 2.062B 1.452B 1.002B 828.132M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price — 35.57 32.55 33.79 —
Price performance 12m — 0.1 -0.09 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Giant Biogene Holding Co., Ltd (ticker 2367), listed in Hong Kong.

ETFs Holding Giant Biogene Holding Co., Ltd

ETF Weight in ETF Shares Market value As of
AVEE 0.14% 72,800 $ 186.249K Nov 16, 2026
AVEM 0.01% 1,423,400 $ 3.642M Nov 16, 2026
DFAX 0.00% 54,600 $ 142.405K Nov 12, 2026